Teva launches generic Tarceva
Teva is introducing a generic version of Genentech's Tarceva (erlotinib) tablets in 100- and 150-mg dosage strengths.
Erlotinib tablets are a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen.
Erlotinib tablets also are indicated for first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer in combination with gemcitabine.
“The launch of generic Tarceva tablets marks an important addition to our offering of oncology products,” Brendan O’Grady, executive vice president and head of North America commercial said.
Tarceva tablets have a market value of $202 million, according to IQVIA data as of February 2019.
Erlotinib tablets are a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen.
Erlotinib tablets also are indicated for first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer in combination with gemcitabine.
“The launch of generic Tarceva tablets marks an important addition to our offering of oncology products,” Brendan O’Grady, executive vice president and head of North America commercial said.
Tarceva tablets have a market value of $202 million, according to IQVIA data as of February 2019.